Lakefront Biotherapeutics NV current report, Q3 FY2025

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of July 2025. The filing, dated July 24, 2025, serves to incorporate by reference a press release issued on July 23, 2025 (Exhibit 99.1). The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Key Financial Metrics

The provided filing text does not contain specific financial data. It is a procedural filing designed to distribute a press release. Consequently, no values are available for revenue, profit, cash flow, margins, debt, or liquidity within this document.

Material Changes

The filing text does not disclose specific material changes to financial position or operations. The primary content is the incorporation of an external press release (Exhibit 99.1), the text of which is not included in the provided input.

Guidance, Outlook, and Risks

No guidance, outlook, management commentary, or risk factors are detailed in the provided text. The document notes that quotes from Henry Gosebruch, Sooin Kwon, and Dan Grossman are included in the attached Exhibit 99.1 but are excluded from the incorporation by reference into the Company's Registration Statements on Form S-8.

Investor Verification Checklist

  • Verify the actual content of Exhibit 99.1 (Press Release dated July 23, 2025) to understand the specific corporate event or announcement triggering this filing.
  • Confirm the discrepancy between the metadata company name ("Lakefront Biotherapeutics NV") and the registrant name in the filing ("Galapagos NV").
  • Review the referenced Form S-8 Registration Statements to understand the context of the excluded quotes.
  • Check subsequent filings for financial updates, as this 6-K contains no numerical financial data.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.